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NMDA receptors are selectively partitioned into
complexes and supercomplexes during synapse
maturation
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How neuronal proteomes self-organize is poorly understood because of their inherent
molecular and cellular complexity. Here, focusing on mammalian synapses we use blue-native
PAGE and ‘gene-tagging’ of GluN1 to report the ﬁrst biochemical puriﬁcation of endogenous
NMDA receptors (NMDARs) directly from adult mouse brain. We show that NMDARs
partition between two discrete populations of receptor complexes and B1.5MDa super-
complexes. We tested the assembly mechanism with six mouse mutants, which
indicates a tripartite requirement of GluN2B, PSD93 and PSD95 gate the incorporation of
receptors into B1.5MDa supercomplexes, independent of either canonical PDZ-ligands or
GluN2A. Supporting the essential role of GluN2B, quantitative gene-tagging revealed a
fourfold molar excess of GluN2B over GluN2A in adult forebrain. NMDAR supercomplexes
are assembled late in postnatal development and triggered by synapse maturation involving
epigenetic and activity-dependent mechanisms. Finally, screening the quaternary organization
of 60 native proteins identiﬁed numerous discrete supercomplexes that populate the
mammalian synapse.
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S
ynapses contain highly complex proteomes that when
disrupted by mutations cause over 100 brain diseases1,2.
Since the function of almost all cellular proteins is
dependent on their higher-order assembly into ‘molecular
machines’3,4, it is imperative to characterize the self-assembly of
synapse proteins and the impact of mutations. However, deﬁning
the organization of the myriad synapse proteins is poorly
understood largely because of the technical challenges imposed
by the cellular and molecular complexity of the brain.
Canonical models of the higher-order assembly of proteins are
hierarchical (Fig. 1a) with individual constituent subunits
forming oligomeric complexes that may further associate into
mega-Dalton sized supercomplexes (complexes of complexes)5.
Amongst the most highly studied examples of synaptic
multiprotein machines are those comprising the N-methyl-D-
aspartic acid receptors (NMDAR) and Dlg/MAGUK proteins,
which are key mediators of synaptic plasticity, cognitive functions
and implicated in multiple brain disorders6–11. The ﬁnding that
PDZ-ligands in GluN2 subunits of NMDARs bind the PDZ
domains of Dlg/MAGUK proteins has underpinned the general
paradigm that neurotransmitter receptors and other classes of
synaptic proteins require this interaction for the purpose of
anchoring and assembly with additional proteins12–15. However,
it is not known if the promiscuity of PDZ interactions is sufﬁcient
for assembly in vivo or if other mechanisms select for the
assembly of speciﬁc combinations of synaptic proteins16.
The study of higher-order protein assemblies in mammals is
further complicated by the evolution of more complex synapse
proteomes in the vertebrate lineage17. A major feature
distinguishing vertebrate from invertebrate synapses is the
expansion in proteome complexity that arose following two
genome duplications in early chordates18–20. The increase in
number of subunits may have had a multiplicative impact on the
diversity of potential vertebrate complexes and supercomplexes.
This is exempliﬁed by the NMDAR-Dlg/MAGUK assembly:
many invertebrate genomes encode a single-GluN2 and -Dlg
protein21, whereas mammals express four, each retaining the
conserved PDZ binding capacity and thereby permitting
16 combinations of GluN2-Dlg/MAGUK interactions. In the
absence of existing methods that enable the efﬁcient
puriﬁcation of intact native NMDAR-Dlg/MAGUK complexes
from the mammalian brain, the actual diversity of vertebrate
complexes/supercomplexes remains unknown. Furthermore,
whether the redundant PDZ-ligand interactions confer
resilience to mutations in individual GluN2 or Dlg paralogs is
unknown because of the lack of studies testing paralog mutations
on complex formation. These issues are fundamental to our
understanding of the molecular organization of the synapse as
well as the interpretation of the growing body of literature
that has identiﬁed disease-causing mutations in NMDAR-
Dlg/MAGUK complexes and other postsynaptic proteins2,22.
To address these issues we developed a biochemical and mouse
genetic approach to characterize the supermolecular organization
of proteomes in vivo, focusing on native NMDAR complexes.
First, using a simple biochemical screen we identify that all native
NMDAR from the mouse forebrain are partitioned between
B0.8 andB1.5MDa complexes. Next, we report the knock-in of
a high-afﬁnity peptide tag into the gene encoding GluN1 subunit
of the NMDAR in mouse. This enables the puriﬁcation of all
endogenous NMDARs, as well as the identiﬁcation and
quantiﬁcation of constituents. Subunit tagging combined with
multiple other mutant mice revealed a novel tripartite mechanism
for assembly between NMDAR, PSD95 and PSD93 super-
complexes. This mechanism regulates assembly late in postnatal
development. Supercomplex assembly is also driven by
synapse maturation involving epigenetic and activity-dependent
palmitoylation. Finally, we used a biochemical screen to survey 60
diverse proteins from within the synapse proteome identifying
their higher-order organization into 190 novel complexes and
supercomplexes consistent with those containing NMDARs.
These ﬁndings reveal speciﬁc mechanisms that restrict the
association of synapse proteins into speciﬁc supercomplexes
and identify a role in synapse maturation.
Results
Two supermolecular NMDAR complexes in mice and humans.
Numerous reports using co-immunoprecipitation and in vitro
methods have shown that NMDARs are associated with upwards
of 50 different synaptic proteins, which are expected to affect the
Ca2þ -dependent synaptic signalling, anchoring and trafﬁcking of
NMDARs. How these apparently numerous binary interactions
relate to the assembly of native NMDARs is unknown. For
example, does the native forebrain NMDAR complex contain all
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Figure 1 | Native supermolecular assembly of NMDAR subunits in the mammalian brain. (a) Schematic showing the higher-order assembly from
individual proteins to complexes and supercomplexes (complexes of complexes). (b) Native protein complexes of GluN1, GluN2A and GluN2B detected in
BNP immunoblot screen of mouse forebrain extracts. Approximately 0.8 and B1.5MDa complexes indicated by ﬁlled and open arrowheads, respectively
(hereafter used to label all ﬁgures). The expected size of each protein in monomeric form indicated with pink rectangle. On left side, non-denaturing
molecular mass indicated in mega-Daltons (MDa). (c) BNP GluN1 immunoblot of fractions from glycerol gradient (10–30%) ultracentrifugation. ‘IN’,
forebrain extract supernatant. On right side, non-denaturing molecular mass indicated in MDa. (d) BNP GluN1 immunoblot of fresh human cortical biopsy
samples from the inferior frontal (inf. front.), inferior temporal (inf. temp.) and superior frontal (sup. front.) lobes. Mouse forebrain extract supernatant
shown for comparison. These data show theB0.8 andB1.5MDa NMDA receptor complexes (1.5-NR and 0.8-NR) were conserved between mouse and
humans.
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of these components all of the time? To address this question we
employed blue-native polyacrylamide gel electrophoresis (BNP)23
to explore the size distribution of the total population of
NMDARs in the mouse forebrain. In contrast to co-
immunoprecipitation, this permitted us to identify the distinct
complexes within which each brain protein reside, without
requiring prior knowledge of their constituents. BNPs showed
native NMDARs (containing GluN1, GluN2A and GluN2B) were
distributed between only two distinct complexes with apparent
median masses of B840 kDa and B1.5MDa (Fig. 1b), for
simplicity hereafter referred to as 0.8-NR and 1.5-NR,
respectively. Although the detergent-lipid micelle surrounding
0.8-NR and 1.5-NR likely contributes to the observed masses,
both were also separable on the basis of size by ultracentrifugation
through a glycerol gradient (Fig. 1c), conﬁrming these molecular
species were distinct. The existence of NMDARs in these two
forms has not been reported previously and we therefore
examined whether both were detectable in human brain. BNP
immunoblots probed with GluN1 (Fig. 1d) conﬁrmed both
0.8-NR and 1.5-NR in extracts from neurosurgical biopsies
of the human neocortex. These data suggest that two distinct
supermolecular forms differing in size constitute native NMDARs
of the adult mammalian forebrain.
Isolation of native NMDAR complexes from Glun1TAP mice.
To understand the molecular basis for the partitioning of
NMDARs into two supermolecular forms requires identiﬁcation
of constituents that distinguish 0.8-NR from 1.5-NR. Puriﬁcation
of scarce native assemblies from complex tissues typically suffers
from low yields and the absence of reliable controls. To avert this
problem, we used mouse genetics to insert a tandem afﬁnity
puriﬁcation (TAP) tag into the ﬁrst protein-coding exon of the
GluN1 subunit gene (Glun1) by homologous recombination in
embryonic stem cells (Fig. 2a). Because most proteomic methods
rely on denaturation to elute puriﬁed complexes, which prevents
individual complexes from being separated from one another, we
included a 3xFlag tag. This design permitted gentle elution (by
competition with 3xFlag peptide) of intact individual complexes
for further separation and characterization (Supplementary
Fig. 1a).
Following germline transmission of this TAP-GluN1 knock-in
mutation (Glun1TAP/þ ), mice were intercrossed to produce viable
Glun1TAP/TAP homozygotes. Next, these mice were examined in
biochemical, anatomical and electrophysiological assays, which
indicated that the TAP-tagged NMDAR functioned normally
(Supplementary Fig. 1b–g). Optimization of the puriﬁcation
conditions resulted in almost complete solubilization of TAP-
GluN1, GluN2A and GluN2B, thus providing material that was
representative of essentially all endogenous NMDARs (Fig. 2b, lanes
5 and 6 from left and Supplementary Fig. 2a). A single step of Flag-
afﬁnity puriﬁcation (Fig. 2b and Supplementary Fig. 2b) yielded
10–25mg protein from ﬁve adult mice, which corresponds toB1012
receptors per mouse forebrain.
Puriﬁed TAP-NMDARs complexes were directly visible as
coomassie-stained BNP bands equivalent to those detected in
forebrain extract by BNP immunoblot (Fig. 2c, left lane),
indicating the native NMDARs were puriﬁed intact. No bands
were visible in control (wild type (WT)) samples (Fig. 2c, left
lane), indicating the speciﬁcity of the puriﬁcation. To determine
the molecular constituents that might differentiate 0.8-NR from
1.5-NR, we excised each BNP band and proﬁled their composi-
tion using mass spectrometry (BNP-MS, Supplementary Table 1).
A sample of these MS-identiﬁed proteins was validated by BNP
immunoblot (Supplementary Fig. 2c,d), suggesting the 0.8-NR
band was composed solely of NMDAR subunits and represents
the expected ‘classical’ tetrameric channel complex. In contrast,
the 1.5-NR band contained the NMDAR complex in association
with 50 other proteins (see Supplementary Table 1 for full list)
including other ion channel complexes (Kir2.3), trans-synaptic
adhesion (Adam22), scaffold (PSD95, PSD93) and signalling
proteins (CaMKIIa). Thus, the size and composition suggest
1.5-NR represent a sub-population of NMDAR supercomplexes.
To explore the higher-order assembly of synaptic receptor
complexes further we used the same TAP-tag and BNP-MS
strategy to analyse an available Psd95TAP/TAP knock-in mice
line24 and found TAP-puriﬁed PSD95 was readily visible on
coomassie-stained BNP within a single B1.5MDa band (Fig. 2c,
right lane). Thus, essentially all PSD95 assembles intoB1.5MDa
complexes (hereon called 1.5-PSD95). Moreover, MS of the
gel-excised 1.5-PSD95 band identiﬁed 89 proteins, of which 87%
were the same as those in 1.5-NR (Supplementary Table 2). The
constituents of 1.5-NR and 1.5-PSD95 were consistent with the
numerous proteins reported to interact with either NMDAR or
PSD95 (refs 24,25). Importantly, these associations shown here
were all conﬁned within a discrete subset of NMDARs in the
mega-Dalton size range, which is inconsistent with models of
these synaptic proteins co-assembled into either a single very
large complex or distributed within a network.
We therefore reasoned that the majority of 1.5-NR constituents
would be in low abundance. Accordingly, Coomassie-staining of
puriﬁed NMDAR separated by SDS-polyacrylamide gel electro-
phoresis (PAGE) revealed only four major bands (with apparent
molecular weights of 180, 130, 105 and 85 kDa), and many more
bands of lower abundance (Fig. 2d). The principal constituents of
the four abundant bands, identiﬁed by peptide mass ﬁngerprint-
ing, were GluN2A/GluN2B, TAP-GluN1, PSD93 and PSD95,
respectively. These data support a model in which there are many
different 1.5-NR complexes each with different constituents and
also suggest a central role for PSD95 and PSD93. We conﬁrmed
the minimal requirements for the assembly of 0.8-NR and 1.5-NR
by heterologous expression of subunits in HEK cells. Transient
transfection of HEK293 cells with complementary DNAs
encoding GluN1 and GluN2B in HEK293 produced 0.8-NR
(Supplementary Fig. 2e), whereas transient transfection with
complementary DNAs encoding GluN1, GluN2B, PSD95 and
PSD93, produced 0.8-NR and 1.5-NR (Supplementary Fig. 2f).
Other constituents of forebrain 1.5-NR are likely to increase the
range of masses as shown by BNP immunoblot of proteins
co-puriﬁed with TAP-GluN1 (Supplementary Fig. 2d). To test the
speciﬁcity and mechanism of assembly we next used mouse
genetics to mutate constituents of 1.5-NR in vivo.
A tripartite mechanism for the assembly ofB1.5MDa NMDARs.
On the assumption that in vitro GluN2 binds interchangeably
with either PSD95 or PSD93 via the same PDZ-ligand12,13 we
reasoned that a knockout of either MAGUK would not prevent
NMDAR recruitment intoB1.5MDa supercomplexes. However,
Fig. 3a shows that in Psd95 / knockout mice 1.5-NR was
essentially absent from the whole forebrain. Perhaps more
intriguing was the discovery that in Psd93 / knockout mice
1.5-NR also failed to assemble (Fig. 3a). Thus, the interaction of
NMDAR with either PSD95 or PSD93 was not sufﬁcient to
recruit NMDARs intoB1.5MDa complexes; instead both PSD95
and PSD93 were essential.
These genetic interdependencies for 1.5-NR assembly
were highly selective because in Psd95 / mice 1.5-PSD93
remain and in Psd93 / most 1.5-PSD95 were still present
(Supplementary Fig. 3). This result also indicates that a large
population of PSD95 and PSD93 must exist in complexes that are
independent of NMDARs.
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One potential explanation for the dual genetic dependency of
PSD95 and PSD93 for 1.5-NR assembly is that the PDZ-ligand
interactions with GluN2A/B are not sufﬁcient in vivo. To test
directly the necessity of PDZ-ligands in vivo we engineered
double mutant mice that lacked both GluN2A and GluN2B
PDZ-ligands in their C-termini. First, we targeted a point
mutation that deletes the C-terminal valine from the gene
encoding GluN2B, producing Glun2bdV mice (Supplementary
Fig. 4a). Glun2bdV/dV homozygous mice were viable and fertile.
Next, to render forebrain NMDARs completely devoid of
C-terminal PDZ-ligands on both GluN2A and GluN2B, we
crossed Glun2bdV/dV with another available line in which the
entire carboxy-terminal domain (CTD) of GluN2A was deleted
(Glun2adC/dC mice)26. The resulting NR-DPDZlig double
knock-in mice were crossed with Glun1TAP to produce
Glun2bdV/dV/Glun2adC/dC/Glun1TAP/TAP triple homozygous
knock-in mutants that enable puriﬁcation of receptors from
NR-DPDZlig mice (Fig. 3b, left). Remarkably, in NR-DPDZlig
mice the assembly of NMDARs into 1.5-NR was preserved
(Fig. 3b, right). We conﬁrmed the association between NMDARs,
PSD95 and PSD93 in the absence of PDZ-ligands by detecting
PSD95 and PSD93 in 1.5-NR puriﬁed from NR-DPDZlig mice
(Fig. 3c). Although the PDZ-ligand was not essential for the
assembly of 1.5-NR, we observed a notable reduction in the total
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Figure 2 | Generation of TAP-tagged GluN1 (Glun1TAP/TAP) knock-in mice for puriﬁcation of native NMDARs. (a) Genetic engineering of TAP-tags into
GluN1. Left, schematic shows tetrameric NMDAR with two GluN1 subunits (grey) engineered with tandem afﬁnity peptide (TAP-tags, magenta) on their
extracellular N-termini. GluN2 subunits (GluN2A, cyan; GluN2B, orange) shown with C-terminal cytoplasmic ESDV motifs/PDZ-ligands. TAP-tag encodes
3xFlag and Hisx6. Right, schematic shows gene-targeting vector carrying TAP-tag sequence in Glun1 exon1, 5
0 and 30 regions of homology with genome and
resultant targeted allele below. The neomycin selection cassette was subsequently deleted using Cre/loxP. Grey-ﬁlled boxes, exons; magenta, TAP cassette;
brown box, neo neomycin resistance cassette; brown triangle, loxP site; dotted lines, homology arms. (b) Puriﬁcation of native NMDARs from Glun1TAP/TAP
mouse forebrains. Left, schematic of puriﬁcation steps and samples corresponding to right, immunoblots of NMDAR subunits, PSD95, actin. Dissected
mouse forebrains were homogenized and fractionated. Crude membrane fraction was solubilized (membrane extract) and separated by centrifugation
(supernatant and pellet). Supernatant was incubated with Flag-afﬁnity resin capturing TAP-tagged receptors with some residual Flow-through. High yields
of native receptor were released (eluate) by peptide-antigen exchange. Following elution no material remained (exchanged resin). Right, puriﬁcation from
Glun1TAP/TAP (TAP) and WTcontrol mouse shows receptor subunits (GluN1, GluN2A, GluN2B), PSD95, and actin detected by SDS–PAGE immunoblots from
indicated fractions. Note the higher molecular weight of TAP-engineered GluN1 compared with WT. IB, immunoblotting antibody; MW, molecular weight
markers. SDS, SDS–PAGE. (c) Coomassie-stained BNP of TAP-puriﬁed NMDAR and PSD95 complexes from Glun1TAP/TAP and Psd95TAP/TAP mice,
respectively. TAP-puriﬁed complexes isolated from forebrain extracts from control (WT), Glun1TAP/TAP and Psd95TAP/TAP mice were separated on BNP gel
and Coomassie stained. Supplementary Fig. 2a shows excised bands used in native proteomic analysis (TAP-BNP-MS). Filled arrow indicates B1.5MDa
complexes and open arrow indicates 0.8-NR. Molecular weight in MDa shown on left and in stained ladder in ﬁrst and last gel lanes. (d) Coomassie-stained
SDS–PAGE of TAP-puriﬁed NMDARs from Glun1TAP/TAP and control (WT) mice. Abundant constituents of bands 1–4 were identiﬁed by MALDI-MS:
GluN2A/B, TAP-GluN1, PSD93 and PSD95, respectively. MW shown in kDa on left.
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expression levels of all NMDAR subunits (GluN1, GluN2A
and GluN2B) in NR-DPDZlig mice (Supplementary Fig. 4b),
suggesting the PDZ-ligand inﬂuences receptor biogenesis or
trafﬁcking27.
Having established that the PDZ-ligand interaction was
dispensable, we reasoned that the mechanism of NMDAR
assembly with MAGUKs could be mediated by sequences other
than the conserved ESDV motif within the GluN2 CTDs (ref. 28).
The CTD is the most divergent domain between GluN2A and
GluN2B paralogs21, raising the possibility that only one of these
two paralogs was capable of directing assembly of NMDARs into
1.5-NR. To test the role of GluN2A and GluN2B CTDs we
examined two knock-in mutant mice lines. In the ﬁrst mutant,
Glun2b2A(CTR)/2A(CTR), mice express only GluN2A CTDs (the
exon encoding the GluN2B CTD has been replaced with a copy of
the exon that encodes the GluN2A CTD)20.
In the forebrains of homozygous Glun2b2A(CTR)/2A(CTR) mice
the NMDAR was almost completely absent from the B1.5MDa
supercomplexes, leaving only 0.8-NR (Fig. 3d). Thus, GluN2A
CTDs were insufﬁcient to replace GluN2B CTDs for assembling
NMDARs with PSD95 in 1.5-NRs. In accordance, in
Glun2a2B(CTR)/2B(CTR) knock-in mice that only express the
GluN2B CTD (the exon encoding the GluN2B CTD is inserted
into the GluN2A gene) we found NMDARs assembled into both
B1.5 and B0.8MDa complexes (Fig. 3d and Supplementary
Fig. 3). Thus, the CTD of GluN2B speciﬁcally assembles
NMDAR-Dlg/MAGUK supercomplexes independent of its
PDZ-ligand.
These genetic ﬁndings make the prediction that the higher-
order assembly of receptor tetramers into 1.5-NRs is not
promiscuous because it is essential for any given tetramer to
contain a minimum of one GluN2B subunit; those receptors
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Figure 3 | Mutant mouse screen of NMDAR supermolecular assembly. (a) Left, BNP GluN1 immunoblot of forebrain extracts WT (lanes 1 and 2,
duplicates), Psd95 / (lanes 3 and 4), Psd93 / (lanes 5 and 6). Right panel, quantiﬁcation shows relative to WT (n¼6) 1.5-NR decreased to 17%
(Po0.001) and 15% (Po0.001) in Psd95 / (n¼ 6) and Psd93 / (n¼ 6) mice, respectively. (b) Assembly of 1.5-NR does not require conserved PDZ-
ligands. Left, schematic of NMDAR in NR-DPDZlig mice (Glun2bdV/dV/Glun2adC/dC/Glun1TAP/TAP). The receptor lacks the GluN2A CTD and terminal valine of
GluN2B ESDV motif and contains the TAP-tagged GluN1. GluN1 subunit, grey; TAP-tags, magenta; GluN2A subunit, cyan; GluN2B subunit, orange. Right,
BNP immunoblot of NR-DPDZlig forebrain extracts (lanes 3 and 4) and control (Glun1TAP/TAP; lanes 1 and 2) mice with Flag antibody detecting TAP-GluN1.
Sample load was normalized by total NMDAR concentration (Supplementary Fig. 4b). (c) PSD95 and PSD93 assemble with NMDARs in 1.5-NR from NR-
DPDZlig mice. 1.5-NR was TAP-puriﬁed NR-DPDZlig mice (shown as duplicate lanes labelled 1 and 2) and BNPs immunoblotted with antibodies to PSD95
(left panel) and PSD93 (right panel). (d) Assembly of 1.5-NR requires GluN2B CTD and does not require GluN2A CTD. Left, BNP GluN1 immunoblot of
forebrain extracts fromWT (lanes 1 and 2, duplicates), Glun2b2A(CTR)/2A(CTR) (lanes 3 and 4), Glun2a2B(CTR)/2B(CTR) (lanes 5 and 6) mice. Cyan and orange
labels indicate chimeric Glun2a and Glun2b knock-in mutations, respectively20. Right, quantiﬁcation shows in Glun2b2A(CTR)/2A(CTR) mice 1.5-NR decreased
to 6% (t-test, Po0.001) of WT (n¼6). (e) Immuno-depletion of GluN2B or PSD95 removes all 1.5-NR. Extracts from Glun1TAP/TAP/Psd95EGFP/EGFP double
knock-in mice were subunit-depleted with antibodies (shown in lanes) then separated on BNP for immunoblotting with Flag antibody to detect NMDARs.
Lanes; input, total extract; immuno-depleting antibodies (from left to right): non-speciﬁc IgG, GluN2A, GluN2B and GFP. See Supplementary Fig. 4c for
controls. (f) Schematic summary of tripartite genetic requirements of Glun2b, Psd95 and Psd92 for the assembly of B1.5MDa NMDAR supercomplexes.
GluN2A and GluN2B subunits assemble into three 0.8-NR subtypes (complexes of GluN2A di-heteromers, GluN2A/GluN2B tri-heteromers, GluN2B
di-tetramers). GluN1 subunit, grey; GluN2A subunit, cyan; GluN2B subunit, orange. BNP, blue-native PAGE. Molecular weight in MDa shown on right.
Error bars indicate s.e.m. Representative results from triplicate experiments shown. IB, immunoblot.
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containing only GluN2A subunits will be excluded from the
population of 1.5-NRs (Fig. 3d). We tested this biochemically by
depleting all GluN2B-containing receptors from extracts and, as
predicted, BNP immunoblots showed no detectable 1.5-NR
(Fig. 3e, immunodepletion controls in Supplementary Fig. 4c).
Indeed, most receptors including 0.8-NR were also removed,
indicating the majority of native NMDARs contained at least one
GluN2B in the adult forebrain. In contrast, subunit-depleting
GluN2A-containing complexes, removed only a small fraction of
1.5-NR (Fig. 3e), which corresponded to heterotetramers
containing a single GluN2A and GluN2B subunit.
Similarly, when both PSD95 and PSD93 were immuno-
depleted, all detectable 1.5-NR was removed from the sample
(Fig. 3e), while the amount of 0.8-NR remained unaffected. To
deplete just PSD95 and rule out the possibility that PSD95
antibodies were non-speciﬁc, we used a knock-in mouse carrying
an in-frame, C-terminal GFP-tag targeted to the gene encoding
PSD95 (Psd95EGFP/EGFP, reported elsewhere). Immuno-depleting
GFP from the brain extracts of Psd95EGFP/EGFP-Glun1TAP/TAP
double knock-in mice also removed all 1.5-NR (Fig. 3e). There-
fore, every 1.5-NR must contain at least one molecule of PSD95.
Together these genetic and biochemical results indicate a
mechanism of 1.5-NR assembly that was applicable across the
mouse forebrain and required three components: PSD95, PSD93
and the CTD of GluN2B (Fig. 3f).
GluN2B is fourfold more abundant than GluN2A in forebrain.
The immuno-depletion experiments indicated that almost all
NMDARs contain a GluN2B subunit and that very few contain
GluN2A (Fig. 3e), yet prevailing models suggest GluN2A is the
most abundant GluN2 subunit in the adult forebrain7,29,30 or that
the major population of NMDARs are triheteromeric11,31,32.
To investigate this discrepancy further, a genetic tagging assay
was devised to measure the molar ratio of GluN2A/GluN2B
expression in vivo using the Glun2b2A(CTR)/2A(CTR) knock-in
mice. First, we showed by immunoblotting the N-terminal
domain that replacing the CTD of GluN2B with that of
GluN2A in Glun2b2A(CTR)/2A(CTR) mice caused no change in
the total expression levels of GluN2A, GluN2B or GluN1
compared with WT (Fig. 4a, bottom three panels). Next, we
measured in total forebrain extracts the relative amount
of the GluN2A CTD and found it was ﬁvefold greater in
Glun2b2A(CTR)/2A(CTR) compared with WT (Fig. 4a, top panel).
This indicates that the molar ratio of GluN2A to GluN2B was
1:4±1 (mean±s.d.) in the adult forebrain (Fig. 4b,c and Methods
section ‘Quantiﬁcation of subunit molar ratios in vivo’).
As a further control, we performed the reciprocal measurement
of the GluN2B CTD in Glun2a2B(CTR)/2B(CTR) mice20. In
accordance with the observation that GluN2A subunits were
expressed at much lower abundance than GluN2B in the adult
forebrain, the amount of GluN2B detected with antibodies that
recognize the GluN2B CTD was only slightly greater in
Glun2a2B(CTR)/2B(CTR) compared with WT (Fig. 4a, second from
top panel, Fig. 4b–c).
Different brain regions might have different molar ratios of
GluN2A to GluN2B that could skew the overall average;
therefore, we measured the molar ratio of GluN2A to GluN2B
within eight distinct brain regions of the adult mouse. As
expected, GluN2A was more abundant than GluN2B within the
cerebellum (Fig. 4d,e). In the cortex and hippocampus, GluN2B
was six- and threefold more abundant than GluN2A, respectively.
In the hindbrain, GluN2A and GluN2B were present at near
equimolar amounts. In all other brain regions a three- to
sixfold excess of GluN2B over GluN2A was detected (Fig. 4e).
Quantiﬁcation of the excess of GluN2B over GluN2A is therefore
widespread and consistent with the importance of GluN2B for the
assembly of 1.5MDa supercomplexes in the forebrain.
Supercomplex assembly in synapse maturation. Having
established the composition and genetic dependencies, we next
sought to understand the functional context of NMDAR and
PSD95 supercomplexes. An extensive literature has highlighted
the importance of NMDAR and PSD95 in the postnatal
development and synapse maturation of the mammalian brain33.
We hypothesized that the two NMDAR complexes found in the
adult brain may be subject to differential regulation during
development.
We compared the native assembly of NMDAR complexes at
multiple postnatal ages, from birth (P1) to adulthood (P69) in the
mouse forebrain, a period marked by profound synaptogenesis
and synapse maturation. At all ages we observed 0.8-NR
complexes (Fig. 5a), whereas signiﬁcant amounts of 1.5-NR were
seen only from P16 onwards (Fig. 5b). In keeping with the
tripartite mechanism of assembly, 1.5-PSD95 and 1.5-PSD93
were absent in the ﬁrst postnatal week and increase signiﬁcantly
from the second postnatal week onwards (Fig. 5a). Thus, 0.8-NR
is constitutively expressed at all ages, whereas 1.5-NR assembly is
developmentally regulated and characteristic of the mature
forebrain.
We therefore wondered if the late postnatal re-organization
of synaptic proteins into supercomplexes was a property of
synapse maturation34–38. Epigenetic mechanisms involving
histone deacetylases have been reported to regulate synapses
maturation39, stabilize memory and enhance memory retrieval in
mouse models of Alzheimer’s disease40,41. To test the role of
supermolecular assembly in synapse maturation we used an
inhibitor of HDAC1/2, trichostatin A (TSA), in primary neuronal
cultures39,42. We found DIV7 primary neuronal cells, similar to
the early postnatal forebrain, contain only trace amounts of
1.5-NR. Following 18–24 h TSA treatment, we observed a
signiﬁcant recruitment of PSD95 from its monomeric form into
1.5-PSD95 supercomplexes over control cells (Fig. 6a,b). This
TSA-stimulated synapse maturation also caused a signiﬁcant
decrease of 0.8-NR and increase of 1.5-NR (Fig. 6c,d). These
ﬁndings suggest epigenetic mechanisms can regulate the assembly
of 1.5-NR and 1.5-PSD95 during synapse maturation.
The punctate distribution of PSD95 that is characteristic
of mature synapses can be reversed using inhibitors of
palmitoylation43. To test a structural role of palmitoylation in
1.5-PSD95 assembly we chemically de-palmitoylated proteins in
forebrain extracts by nucleophilic thiolysis (with 40mM MESNA
or 40mM b-mercaptoethanol)44, which had no effect on
the assembly 1.5-PSD95 (Supplementary Fig. 5a). Thus,
palmitoylation per se is not necessary for maintaining PSD95
within 1.5MDa supercomplexes. Since palmitoylation also
regulates trafﬁcking45, we tested if instead palmitoylation
had an indirect inﬂuence on the assembly of 1.5-PSD95.
Treating DIV14 primary neurons for 8 h with an inhibitor of
palmitoylation, 2-bromopalmitate (2BP) caused a dramatic
disassembly of 1.5-PSD95 (Fig. 6g,f), without affecting total
expression of PSD95 (Fig. 6g). The effect of 2BP on 1.5-NR could
not be determined because primary neurons cultured from 14 to
28 days contain only trace amounts of 1.5-NR compared with
neurons within the intact forebrain (Fig. 6c). The 2BP-dependent
decrease in 1.5-PSD95 was rescued by blocking activity with 1 mM
TTX or inhibiting NMDARs with 50mM AP5 (Fig. 6h,i),
suggesting activity-dependent palmitoylation cycling43 regulates
the dynamics of 1.5-PSD95 assembly. The 2BP-dependent
decrease in 1.5-PSD95 coincided with a reduction in the
punctate distribution of PSD95 (Supplementary Fig. 5b) as
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previously reported43. Together these results show the late
postnatal assembly of supercomplexes is determined by the
tripartite mechanism and can be modulated by epigenetic,
palmitoylation and activity-dependent processes.
Higher-order molecular architecture of the synapse. Finally, we
asked if the organizational principles identiﬁed for NMDARs
were consistent with the higher-order assembly of 60 diverse
proteins within the synaptic proteome. Total mouse forebrain
synaptoneurosomes were solubilized in a screen of ﬁve buffers
(with different detergents of varying stringency), then rapidly
resolved by blue non-denaturing-PAGE (BNP), and proteins
detected by immunoblotting (see Methods section for details).
As shown in Fig. 7, we examined proteins from six major
functional modalities of the synapse: neurotransmitter receptors,
trans-synaptic/adhesion, ion channels, signalling enzymes,
scaffolds/adaptors and immediate-early/local translation.
Strikingly, every protein was tethered in at least one complex,
typically 5–20x its monomeric size, consistent with expectations
that almost all individual proteins function within higher-order
assemblies4. After correcting for the potential over-estimation of
mass (r100 kDa) as a consequence of the contribution of the
detergent/lipid micelle, we found only 13 bands corresponded to
the size of native proteins unassembled in monomeric form. This
left 220 reproducible and separable protein bands that likely
represent the major populations of the candidate proteins.
Each band was assigned as a complex and compared with
previously published results (Supplementary Data 1). Seventeen
bands corresponded to the size of known oligomeric complexes
including multiple native AMPA receptor and auxiliary subunits
that co-migrated in B700 kDa complexes46. The remaining
190 bands were many times larger than the monomeric size of
the protein, indicating the existence of many novel complexes
or supercomplexes. As expected from the MS analysis of
TAP-puriﬁed NMDAR and PSD95, we observed 15 constituent
proteins including Kir2.3, Arc and Iqsec2 with bands
co-migrating at B1.5MDa molecular weight (Fig. 7 and listed
in Supplementary Data 1, column D, orange), indicating a
large fraction of the population these proteins assemble into
supercomplexes.
Lastly, we examined the complexes from a subset of proteins
within our screen (mGluR1/5, Arc, b-catenin and NF-kB) at
multiple postnatal ages between P1 and P69 (Supplementary
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Fig. 5c) revealing several different temporal proﬁles of super-
molecular assembly, and thus suggesting the regulated assembly
of synaptic supercomplexes is a widespread property of postnatal
development.
Discussion
This integrative biochemical and genetic analysis identiﬁes
mechanisms controlling the higher-order assembly of proteins
within the mammalian synapse proteome and novel super-
molecular forms of the NMDAR. Endogenous NMDARs were
partitioned within two discrete populations of 0.8 and 1.5MDa,
which were biochemically, genetically and developmentally
separable. The former was expressed at all postnatal ages and
the latter ﬁrst appeared late in postnatal development and driven
by synapse maturation. Genetic dissection of the two super-
molecular forms using a battery of mutant mice revealed 1.5-NR
assembly was critically dependent on a tripartite requirement of
PSD95, PSD93 and GluN2B. A screen of the quaternary
organization of 60 additional synapse-associated proteins
revealed 190 separable complexes and supercomplexes within
the mouse forebrain that were congruent with the constituents
1.5-NR.
Surprisingly, three ﬁndings were inconsistent with the
prevailing model that 1.5-NR assembly is mediated by C-terminal
PDZ-ligands binding to Dlg/MAGUK proteins. First, we found
the GluN2A and GluN2B ESDV ligands were not required
in vivo. Second, we found that both PSD95 and PSD93 were
necessary (either MAGUK alone was not sufﬁcient for the
assembly of NMDAR with PSD95). Third, we found that the
cytoplasmic domain of GluN2A could not assemble with
PSD95 and/or PSD93, whereas GluN2B alone was sufﬁcient
(independent of its PDZ-ligand). Although our ﬁndings do not
support the PDZ-ligand-dependent assembly of NMDARs with
Dlg/MAGUK proteins, the reduced overall levels of NMDAR
expression in mice lacking GluN2A/B PDZ-ligands indicates the
importance of this interaction in the biogenesis or trafﬁcking of
the receptor before assembly with Dlg/MAGUKs into synaptic
supercomplexes. Moreover, both the developmental and genetic
investigations of 0.8-NR and 1.5-NR show that the PDZ-ligand
interaction with Dlg/MAGUKs is not required for synaptic
localization of NMDARs: 1.5-NRs were absent during the ﬁrst 12
postnatal days (when NMDA function is essential) and the three
mutants lacking 1.5-NRs in adulthood have all been reported to
have normal synaptic NMDAR currents in hippocampus CA1
region20,47–49.
Functional insight was apparent from the regulated assembly of
1.5-NR, and 1.5-PSD95 late in postnatal development from
BP12 onwards. This time point coincides with eye opening and
a period of marked synaptogenesis within the forebrain33,50,51.
Consistent with this developmental regulation we also identiﬁed a
role for 1.5-NR and 1.5-PSD95 in synapse maturation. Blockade
of histone deacetylases in immature primary neurons that has
been reported to accelerate synapse maturation39, increased the
assembly of 1.5-NR and 1.5-PSD95. These data indicate that
epigenetic mechanisms inﬂuence the assembly of synaptic
supercomplexes.
A deﬁning property of maturation is the punctate enrichment
of PSD95 within the postsynaptic membrane, which is regulated
by palmitoylation cycles43. Blockade of palmitoylation signalled
an activity-dependent disassembly of 1.5-PSD95, which as
previously reported43, caused a dramatic decrease in PSD95
puncta. Thus the present data suggest 1.5-PSD95 supercomplexes
are the molecular species responsible for the punctate appearance
of PSD95 that indicates a functionally mature synapse52.
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The quantiﬁcation of GluN2A and GluN2B within populations
of postsynaptic complexes and supercomplexes impact on models
that suggest differential functions for these subunits7,11. We have
shown that in vivo the adult forebrain contains fourfold molar
excess of GluN2B over GluN2A. Most GluN2A was assembled
with GluN2B (in so called triheteromeric receptors)31,53 and
GluN2A is dependent on GluN2B for assembly into B1.5MDa
NMDAR-MAGUK supercomplexes. Moreover, we expect further
subpopulations of these complexes since additional receptors, ion
channels, signalling and trans-synaptic adhesion proteins were
detected as constituents of 1.5-NRs and in discrete 1.5MDa
complexes by BNP immunoblot (Fig. 7). The brain region-speciﬁc
differences in the molar ratio of GluN2A to GluN2B raise the
possibility that supercomplexes with different compositions are
allocated into anatomically distinct synapses.
This study provides new insight into the higher-order
molecular organization of the synapse proteome. Almost all
surveyed proteins were found in novel complexes and super-
complexes. It was also striking that many related proteins (within
the same paralog family) did not all co-migrate, suggesting they
were organized in separable complexes (Fig. 7). For example, the
four members of the MAGUK/Dlg family have each been
reported to interact promiscuously with numerous synaptic
proteins (including NMDAR subunits). However, in our screen
we found MAGUKs were differentially organized with PSD95 and
PSD93 in genetically separable 1.5MDa supercomplexes, whereas
the largest population of Sap97/Dlg1 and Sap102/Dlg3
were retained within smaller (0.2–0.4MDa) complexes. Similar
patterns emerge in comparing proteins within 10 out of 12
paralog families surveyed in our screen (Fig. 7 and Supplementary
Data 1). Interestingly, paralog-mediated restriction together with
the modular arrangement of proteins apparent within our BNP
screen (Fig. 7) are two mechanisms that diminish the combina-
torial molecular complexity of the synapse and thereby overcome
a theoretical ‘complexity brake’ on systems with high numbers of
components such as the brain3,54,55.
Although many disease-associated mutations have been
reported in proteins co-purifying in the 1.5MDa TAP-NR and
TAP-PSD95 supercomplexes (including GluN2A, GluN2B and
PSD93/Dlg2)2,22, this study provides the ﬁrst direct evidence that
mutations disrupt their supermolecular organization at the
synapse. We found the 1.5-NRs were exquisitely sensitive to
mutations in PSD95, PSD93 and GluN2B. There is abundant
evidence of physiological and behavioural changes in mice
carrying mutations in these genes19,20,47,48,56,57. This is
particularly compelling for mutations in PSD95 since we
showed most PSD95 resides within 1.5MDa assemblies. In
humans, PSD93 mutations also cause cognitive impairments in
touchscreen tests of cognition, impacting on the same forms of
learning, cognitive ﬂexibility and attention as those seen in PSD93
mutant mice19. Recurrent de novo mutations in PSD93 and
GluN2 genes are now widely reported in schizophrenia as are
mutations in the sets of proteins isolated in 1.5-NR and
1.5-PSD95 complexes19,58–60. Thus, future studies that dissect
the postsynaptic complexes could shed light on the synaptic
mechanisms of brain disorders.
Methods
BNP screen of synaptic complexes. Forebrains (hippocampus and cortex) were
dissected from adult (P56–70) mice and were homogenized (12 strokes with a
Teﬂon-glass pestle and mortar) in 5ml ice-cold buffer H (1mM Na HEPES pH7.4,
320mM sucrose with protease inhibitors). The homogenate pellet was collected by
centrifugation with 1,000g. (MLA-80, 5,000 r.p.m.) at 2 C for 10min and
re-homogenized (6 strokes) in 2ml buffer H and centrifuged as before. The ﬁrst
and second 1,000g. supernatants were pooled and centrifuged at 18,500g. (MLA80,
19,000 r.p.m.) to pellet the crude membranes. The 18,500g. supernatant was
discarded. Extraction conditions were screened using the crude membrane from
50 to 60mg mouse forebrain re-suspended in 0.5ml buffer H, to which different
detergents in 0.5ml buffer X (100mM NaCl, 50mM tris.Cl pH8) were mixed
for 1 h at 6–10 C. Final detergent concentrations were 1% w/v. Detergents
used: sodium deoxycholate (Figs 1–3 and 5–7), 3-[(3-cholamidopropyl)
dimethylammonio]-1- propanesulfonate (Fig. 6), n-Dodecyl-N,N-Dimethyl-3-
Ammonio-1-Propanesulfonate (Fig. 7), b-D-maltopyranoside (Fig. 7), (Fig. 7).
Next, insoluble proteins were removed from the total extract by centrifugation at
120,000 g. (MLA-80, 50,000 r.p.m.) for 40min at 8 C. BNPs were immediately run
and immunoblotted to detect the native complexes of NMDAR subunits (Fig. 1b)
and 60 additional brain proteins (Fig. 7). In general different detergent buffers gave
similarly sized complexes and the less stringent detergent buffers were less efﬁcient
at solubilizing native complexes. Antibodies and all the native complexes detected
with each detergent buffer are detailed in Supplementary Data 1.
BNP immunoblot and immuno-depletions. BNP was run according to
Scha¨gger23. For immuno-depletions, extract supernatant were incubated with
antibodies to deplete subunits at 6–10 C for 2–16 h. To capture antibody-antigen
complexes, 3mg protein G magnetic beads were added for 30min at 6–10 C.
Additional immunoblots ensured the completeness of immuno-depletions
(Supplementary Fig. 4c).
Generation of Glun1TAP/TAP knock-in mice. Sequence encoding a TAP-tag was
designed for in-frame insertion within exon 1 of the Glun1 gene, downstream of
the predicted signal peptidase cleavage site (Asp22) and before the predicted start
of the amino-terminal domain (Pro23). The tag contained a linker (-PSGSTG-), a
3xFlag epitope tag (-DYKDHDIDYKDDDDK-), linker containing a TEV protease
consensus site (-GTENVLYFQGT-), hexa-histidine tag (-GRSHHHHHH-) and a
linker to the beginning of the amino-terminal domain (-GAS-). The 161-bp
sequence encoding the TAP tag with ﬂanking restriction sites (AgeI and NheI) was
synthesized by ligase chain reaction. Upstream of the tag, 2,249 bp 50 homology
arm was retrieved by recombineering with 500 bp mini-homology arms and mouse
genomic BAC clone (bMQ-32D16) in E. coli EL350. The mini-homology arms
ﬂanked by restriction sites (NotI and ScaI) were synthesized by PCR from mouse
genomic BAC clone. Downstream of the TAP-tag, the 30 ﬂank comprising the 30
end of exon 1 (280 bp) and the ﬁrst 500 bp of intron 1 were retrieved with ﬂanking
restriction sites (NheI and SbfI) by PCR from mouse genomic BAC clone.
Additional restriction sites (NdeI and BsrGI) suitable for genomic southern
genotyping were also included upstream of the SbfI restriction site in this product.
The 50 homology arm, TAP-tag and 30 ﬂank products were assembled sequentially
within an intermediate vector by restriction (NotI/ScaI, ScaI/NheI and NheI/SbfI)
and ligation. This product assembly was placed upstream of a 2-kbp neomycin
selection cassette ﬂanked by lox P sites and restriction sites (SbfI and SpeI) within
the intermediate vector. The product assembly together with the lox P-ﬂanked
Neomycin cassette (2,200 bp) was cut (NotI, SpeI) from the intermediate vector and
ligated into the targeting vector, which also contained a 5-kb 30 homology arm.
This homology arm was built from 500 bp mini homology arms ﬂanked by
restriction sites (SpeI and HindIII), which were synthesized by nested PCR from a
mouse genomic BAC clone and ligated into the targeting vector. The 30 mini
homology arms were used to retrieve the 30 homology arms from the mouse
genomic BAC clone by recombineering in E. coli EL350. The targeting vector also
contained a Diphtheria Toxin A cassette for negative selection of non-homologous
integration.
The linearized targeting vector was electroporated into E14Tg2a ES cells.
ES cell clones mutated by homologous recombination were identiﬁed from
genomic DNA samples by PCR. Six out of 216 ES clones were putative
recombinants. Recombination was conﬁrmed for 2 of these 6 clones by genomic
southern hybridization to regions outside the 50 and 30 homology arms of NdeI
digested genomic DNA. Positive ES clones were microinjected into C57BL/6
blastocysts, which generated chimeras containing 30–70% mutant cells. Chimeras
back-crossed onto 129S5 gave germ line transmission, which was genotyped by
PCR and sequenced from ear biopsy samples.
The neomycin selection cassette that was inserted into the ﬁrst intron of Glun1
(Fig. 2a, right) was removed by backcrossing on a transgenic Cre recombinase-
expressing mouse. Double mutant mice (homozygous at both alleles) containing
Glun1TAP/TAP with other mutations were also bred. Except for developmental
experiments, all mice were adult, age-, gender- and background-matched.
Puriﬁcation of native NMDARs from TAP-tagged knock-in mice. The crude
membranes from 5 P56-P70 Glun1TAP/TAP mouse forebrains were re-suspended in
12.5ml buffer H and extracted with 12.5ml 2% deoxycholate, 100mM NaCl,
50mM Tris.Cl pH8 for 1 h at 6 C. Total extract was centrifuged at 120,000g. for
40min at 8 C. Conditions for immuno-capture, wash and peptide-antigen
exchange elution were screened using a high-throughput puriﬁcation robot
(MAGic sample processor, Invitrogen). For 25ml Glun1TAP/TAP extract super-
natant, 80 mg mouse Flag antibody was coupled to 30mg (500 ml) protein G
magnetic beads (Invitrogen). Receptor was captured from extract supernatant for
2 h. The beads were washed three times with 5ml wash buffer (0.37% w/v sodium
deoxycholate, 0.05mg.ml 1 lipids (1:1:3 POPC:POPE:POG), 150mM NaCl,
50mM Tris.Cl pH8). Flag captured complexes were eluted with 600 ml wash buffer
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supplemented with 0.2mg.ml 1 Flag peptide for 2 h at 6 C. Eluate was buffer
exchanged to remove the Flag elution peptide and concentrated with a 100-kDa
MWCO centrifugal ﬁlter (Amicon) to 35 ml 0.1–0.25mg.ml 1 native NMDAR.
Native proteomics (TAP-BNP-LC-MS/MS). Excised BNP gel slices containing
the puriﬁed proteins were prepared for mass spectrometric analysis by manual
in situ enzymatic digestion. Brieﬂy, the excised protein gel pieces were placed in a
well of a 96-well microtitre plate and de-stained with 50% v/v acetonitrile and
50mM ammonium bicarbonate, reduced with 10mM DTT and alkylated with
55mM iodoacetamide. After alkylation, proteins were digested with 6 ng ml 1
Trypsin (Promega, UK) overnight at 37 C. The resulting peptides were extracted
in 2% v/v formic acid, 2% v/v acetonitrile. The digest was analysed by nano-scale
capillary LC-MS/MS using an Ultimate U3000 HPLC (ThermoScientiﬁc Dionex,
San Jose, USA) to deliver a ﬂow of B300 nlmin 1. A C18 Acclaim PepMap100
5 mm, 100mm 20mm nanoViper (ThermoScientiﬁc Dionex, San Jose, USA),
trapped the peptides before separation on a C18 Acclaim PepMap100 3 mm,
75mm 150mm nanoViper (ThermoScientiﬁc Dionex, San Jose, USA). Peptides
were eluted with a gradient of acetonitrile. The analytical column outlet was
directly interfaced via a modiﬁed nano-ﬂow electrospray ionization source,
with a hybrid dual pressure linear ion trap mass spectrometer (Orbitrap Velos,
ThermoScientiﬁc, San Jose, USA). Data-dependent analysis was carried out, using a
resolution of 30,000 for the full MS spectrum, followed by 10 MS/MS spectra in
the linear ion trap. MS spectra were collected over an m/z range of 300–2,000.
MS/MS scans were collected using a threshold energy of 35 for collision induced
dissociation. LC-MS/MS data were then searched against a protein database
(UniProt KB) using the Mascot search engine programme (Matrix Science, UK)61.
Database search parameters were set with a precursor tolerance of 5 p.p.m. and a
fragment ion mass tolerance of 0.8 Da. Two missed enzyme cleavages were allowed
and variable modiﬁcations for oxidized methionine, carbamidomethyl cysteine,
pyroglutamic acid, phosphorylated serine, threonine, tyrosine, tert-butyloxycarbonyl-
lysine, norbornene-lysine and prop-2-yn-1-yloxycarbonyl-lysine were included.
MS/MS data were validated using the Scaffold programme (Proteome Software
Inc., USA). All data were additionally interrogated manually. Peptide
identiﬁcations were accepted if they could be established at 480.0% probability as
speciﬁed by the Peptide Prophet algorithm62. Protein probabilities were assigned
by the Protein Prophet algorithm62. Using these stringent identiﬁcation
parameters, the rate of false-positive identiﬁcations is o1%. All non-mouse
proteins that were detected but could not be matched to a mouse protein
(in Swissprot-TrEMBL) were not included in the analysis below (foe example,
human keratins).
The composition of B1.5MDa complexes from TAP-GluN1, PSD95-TAP and
WT control were compared (Supplementary Table 1) using a stringent threshold of
detection (Z2 unique peptides and Z1 unique peptide in Z2 replicate samples).
This level of stringency was sufﬁcient to detect 55 proteins in TAP-GluN1, 89
proteins in PSD95-TAP and only one protein in the WT control (IgG). Since it
expected that the ‘tails’ of the bands may partially overlap, the differential
composition of proteins in the B0.8 and B1.5MDa TAP-GluN1 bands were
validated by BNP immunoblot of TAP-puriﬁed complexes (Supplementary
Fig. 2d).
All MS data (raw data, mascot ﬁles and scaffold ﬁle) were processed with the
PRIDE converter63 and deposited in the PRIDE database (http://www.ebi.ac.uk/
pride/)64 with ProteomeXchange accession number: PXD000011.
MALDI-MS. To identify the principle NMDAR constituents (Fig. 2d), 35ml
concentrated TAP-puriﬁed samples were denatured in SDS loading buffer and
separated on a 4–12% bis-tris polyacrylamide gel. The gel was ﬁxed and stained
with colloidal Brilliant Blue-G Coomassie (Sigma). The principle bands were
identiﬁed by MALDI-MS mass ﬁngerprinting. Gel bands were excised and
subjected to the following treatment (30min per step, 20 C, in 100mM
ammonium bicarbonate/50% acetonitrile): (1) Reduction with 5mM tris
(2-carboxyethyl)phosphine. (2) Alkylation by addition of iodoacetamide (25mM
ﬁnal concentration) and (3) removal of liquid then wash. Gel pieces were dried
in vacuo for 10min and 25ml 100mM ammonium bicarbonate containing
10mgml 1 modiﬁed trypsin (Promega) was added. Digestion was for 17 h at
32 C. Peptides were recovered and desalted using uC18 ZipTip (MIllipore) and
eluted to a MALDI target plate using 2 ml a-cyano-4-hydroxycinnamic acid matrix
(Sigma) in 50% acetonitrile/0.1% triﬂuoroacetic acid. Peptide mass were deter-
mined using a MALDI micro MX mass spectrometer (Waters) in reﬂection mode
and analysed with Masslynx software. Database searches of the mass ﬁngerprint
data were performed using Mascot (http://www.matrixscience.com).
Generation of Glun2b2BdV knock-in mice. The Glun2b2BdV knock-in mouse was
engineered by standard mouse genetic protocols in which the GluN2B terminal
valine (1,482) was deleted, leaving the last codon for Asp1471 before the stop
codon (Supplementary Fig. 4a). In brief, 5.9 kb 50 and 1.8 kb 30 homology arms
were used to construct the gene targeting vector for GluN2B terminal valine (1,482)
deletion mutation. The targeting vector also contained a neomycin resistance
cassette (pgk-Neo-pA) ﬂanked by loxP sites at the 30 of the mutation and diphtheria
toxin A cassette for negative selection. A linearized targeting vector was
electroporated into E14TG2a ES cells and positive clones were identiﬁed and
validated by genomic southern blots with 50 and 30 ﬂanking probes (data not
shown). Positive ES clones were injected into C57/BL6 blastocysts to generate
mice chimeric for the Glun2b2BdV mutation. After germline transmission, the
Glun2b2BdV mutants were crossed with a Cre-deleter line and the neo cassette
was removed. Inter-crossing heterozygous mice produced viable homozygous
Glun2b2BdV/2BdV knock-in mutants. The detailed phenotypic characterization
of this mutant will be described elsewhere.
Quantiﬁcation of subunit molar ratios in vivo. Measurements of the molar ratios
of GluN2A/GluN2B were performed using age-matched (P56-P69) total forebrain
(cortex and hippocampus) samples. Quantifying the molar ratios of two different
endogenous mouse proteins was achieved by using targeted mouse genetics to
match an epitope for immuno-detection.
WT control with either Glun2b2A(CTR)/2A(CTR) or Glun2a2B(CTR)/2B(CTR) were
used for two independent measurements of the GluN2A/GluN2B molar ratio
(Fig. 4). In the ﬁrst measurement of the GluN2A/GluN2B molar ratio was made
using Glun2b2A(CTR)/2A(CTR) mice, in which the CTD of GluN2B was replaced with
that of GluN2A. Immunoblotting the amino-terminal domains showed this
domain replacement caused no change in the total expression levels of GluN2A,
GluN2B or GluN1 compared with WT. Next, using a GluN2A CTD speciﬁc
monoclonal antibody gave a measurement of GluN2A in WT mice, and the sum of
GluN2A and GluN2B subunits in Glun2B2A(CTR)/2A(CTR) mice from which the
molar ratio of GluN2A/GluN2B was calculated. Glun2A2B(CTR)/2B(CTR) mice served
as a control for the speciﬁcity of the GluN2A CTD antibody. The reciprocal
measurement of the GluN2B CTD using Glun2a2B(CTR)/2B(CTR) was also performed
using a GluN2B CTD speciﬁc monoclonal antibody. Measurements were
performed by densitometry of immunoblots using a dilution series (Fig. 4b) to
ensure differences in band intensity corresponded to linear differences in the
concentration of these epitopes.
Primary neuronal culture. Primary neuronal cultures of cortical and hippocampal
cells (Supplementary Fig. 1d) were prepared from E17.5 WT and Glun1TAP/TAP
embryos and cultured at 105 cells cm 2 (for imaging) on poly-D-lysine coated glass
cover-slips until they reached DIV7 (for 18–24 h 0.25 mM TSA treatment), DIV14
(for 8 h 10 mM 2-BP treatment). For biochemical analysis, cells were extracted in
100 ml 100:100:1 buffer H, buffer X (containing sodium deoxycholate at 1% w/v
ﬁnal concentration) and 10 kU benzonase at 5 C for 20min.
Immunoﬂuorescence confocal microscopy. Primary neurons were ﬁxed with
methanol, blocked with 3% bovine serum albumin (in 0.5% triton X-100, PBS) for
1 h at RT. Incubations with primary antibody in blocking buffer were for 1 h at RT,
followed by 3 5min wash in PBS. Incubations with secondary antibody in
blocking buffer were for 2 h at RT, followed by 3 5min wash in PBS and 3 5 s
washes in de-ionized water. Cover slips were mounted on slides with antioxidants
and DAPI (antifade, Invitrogen).
Digital photographs of 0.8–1 mm optical sections were collected at on a Zeiss
710 confocal microscope with  63/1.4 numerical aperture objective.
Immunohistochemistry. Homozygous Glun1TAP/TAP and wild-type mice were
anaesthetized with 60mg g 1 avertin and perfused with 10ml PBS, followed by
5ml 4% paraformaldehyde at 2.5mlmin 1. Forebrains were dissected, post-ﬁxed
in 4% paraformaldehyde for 2–4 h and stored at 4 C in 30% sucrose for up to one
week. Sagittal sections (30 mm) were collected with a vibratome. Free-ﬂoating
sections were incubated with 1:500 Rabbit Flag (Genscript, A000187) or 1:200
Rabbit GluN2A (Serotec, AHP1880) in buffer A (0.5% triton X-100, 100mM NaCl,
50mM tris.Cl pH 7.4 overnight at 4 C. Following 3 10min washes with buffer A
at RT, sections were DAB stained with anti-rabbit-HRP using a kit (Vectastain)
and mounted between cover slip and slide.
Slice electrophysiology. Hippocampal slices (400-mm-thick) were prepared using
standard techniques approved by the UCLA Institutional Animal Care and Use
Committee. Slices were maintained in an interface-slice type chambers (at 30 C)
perfused with oxygenated (95% O2/5% CO2) artiﬁcial cerebrospinal ﬂuid
containing 124mM NaCl, 4.4mM KCl, 25mM NaHCO3, 1mM NaH2PO4, 2mM
CaCl2, 1.2mM MgSO4 and 10mM glucose. Techniques described elsewhere48
were used to record ﬁeld excitatory postsynaptic potentials evoked by Schaffer
collateral/commissural ﬁbre stimulation in the hippocampal CA1 region. LTP
was elicited using two trains of 100Hz stimulation, each 1 s in duration, with an
inter-train interval of 10 s. Whole-cell voltage-clamp techniques were used to
record excitatory postsynaptic currents (EPSCs) evoked by Schaffer collateral ﬁbre
stimulation. Patch electrodes (4–6MO) were ﬁlled with a solution containing
102mM caesium gluconate, 17.5mM CsCl, 10mM TEA-Cl, 5mM QX314, 4.0mM
Mg-ATP, 0.3mM tris-GTP and 20mM HEPES (pH¼ 7.2), and slices were bathed
in a modiﬁed artiﬁcial cerebrospinal ﬂuid containing picrotoxin (100 mM), elevated
concentrations of CaCl2 and MgSO4 (4mM each) and 2.4mM KCl. AMPAR-
mediated and NMDAR-mediated components of evoked EPSCs were measured
using current amplitudes 5 and 50ms after EPSC onset, respectively. Double
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exponential ﬁts to the decay of synaptic currents measured at þ 40mV were
used to calculate the weighted mean decay time constant for the decay of
NMDAR-mediated currents65. All results are reported as mean±s.e.m. The results
for the same experiment on multiple slices or cells from the same animal were
averaged and the N used for statistical comparisons (two-tailed Student’s t-tests)
equals the number of animals in each group.
Antibodies. Primary antibodies (dilutions for immunoblot in parenthesis: mouse
Flag (Sigma, F3165) mouse GluN1 (1:1,000, Invitrogen, 32–0500), rabbit GluN1-1
(1:500, Millipore, AB9864), mouse GluN2A (1:1,000, BD Bioscience, 612287),
rabbit GluN2A (1:500, Serotec, AHP1880), mouse GluN2B (1:1,000, BD Bioscience,
610416/7), rabbit GluN2B (1:500, Invitrogen, 71–8,600), mouse PSD95/3 (1:3,000,
Thermo scientiﬁc, MA1–045), mouse PSD93 (1:2,500, Neuromab, 75-057), rabbit
PSD95 (1:1,000. Abcam, ab18258), mouse GFP (Invitrogen, A11120), rabbit GFP
(Invitrogen, A11122). Conjugated antibodies: mouse Flag-HRP (1:40,000, Sigma,
A8592), goat mouse-HRP (1:20,000, Millipore, 12–349) and goat rabbit-HRP
(1:20,000, Millipore, 12–348). Antibodies used for Fig. 7 are listed in
Supplementary Data 1.
SDS–PAGE immunoblot. Images in Figs 2b, 4a,b,d and 6h have been cropped for
presentation. Full size images are presented in Supplementary Figs 6–8,
respectively.
Human brain samples. Three cortical samples were obtained from neurosurgical
operations. Tissue was immediately chilled in ice for 30–40min after which they
were frozen at  70 C. Tissue was not defrosted until used extraction and BNP.
In all cases prior written informed consent had been obtained, and the study
approved by the local regional ethics committee (Lothian Region Ethics Committee
/2004/4/16).
Animals. All animal experiments conformed to the British Home Ofﬁce
Regulations (Animal Scientiﬁc Procedures Act 1986; Project License PPL80/2,337
to Prof Seth Grant), local ethical approval, and NIH guidelines.
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